Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

872
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
872
Antibody Structure01:10

Antibody Structure

51.6K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
51.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and public involvement in dementia and neuroprogressive conditions: commentary from NHS Scotland based 'partners in research'.

Research involvement and engagement·2025
Same author

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Lancet (London, England)·2025
Same author

A pragmatic randomized controlled exploratory trial of the effectiveness of Eye Movement Desensitization and Reprocessing therapy for psychotic disorder.

Journal of psychiatric research·2023
Same author

Location-specific psychosocial and environmental correlates of physical activity and sedentary time in young adolescents: preliminary evidence for location-specific approaches from a cross-sectional observational study.

The international journal of behavioral nutrition and physical activity·2022
Same author

GPS-based activity space exposure to greenness and walkability is associated with increased accelerometer-based physical activity.

Environment international·2022
Same author

[The 32nd emeriti meeting in Düsseldorf 9-12 September 2021].

Zeitschrift fur Rheumatologie·2022

Related Experiment Video

Updated: Apr 27, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

European consensus proposal for immunoglobulin therapies.

W A Carrock Sewell1, Jacqueline Kerr, Marie-Emmanuelle Behr-Gross

  • 1University of Lincoln & Hull York Medical School, UK.

European Journal of Immunology
|July 1, 2014
PubMed
Summary

Immunoglobulin (Ig) therapy use has tripled, increasing healthcare costs and straining plasma supply. Experts developed consensus recommendations for optimal Ig use and prioritized indications to address potential shortages.

Keywords:
AntibodiesImmunodeficienciesImmunoglobulinsImmunopathologyImmunotherapy

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.3K

Related Experiment Videos

Last Updated: Apr 27, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.3K

Area of Science:

  • Immunology
  • Healthcare Management
  • Pharmacoeconomics

Background:

  • Global use of immunoglobulin (Ig) preparations (intravenous, IVIg, and subcutaneous, SCIg) has tripled in 20 years.
  • This surge increases healthcare costs and relies heavily on human plasma collection.
  • Rising diagnoses of primary immunodeficiencies and expanded immunomodulatory uses may lead to plasma supply shortages.

Purpose of the Study:

  • To address the urgent need for consensus recommendations on optimal immunoglobulin (Ig) use.
  • To establish priority rankings for the most critical Ig indications.
  • To ensure sustainable access to essential Ig therapies.

Main Methods:

  • A consensus meeting was held with expert nominees from 36 Council of Europe states.
  • Colleagues from observer countries and regulatory agencies also participated.
  • The outcome was a consensus statement outlining recommendations and priorities.

Main Results:

  • Consensus was reached on the optimal utilization of Ig preparations.
  • Priority indications for Ig therapy were identified and ranked.
  • Recommendations aim to balance clinical need with plasma supply sustainability.

Conclusions:

  • Optimal use of immunoglobulin (Ig) is crucial due to increased demand and limited supply.
  • Consensus recommendations provide a framework for prioritizing Ig therapy.
  • These guidelines support sustainable access to essential immunoglobulin treatments.